Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
HIV-1 envelope glycoprotein gp120 C5 region (gp120 C5)
- Target
- gp120 C5
- Molecular classification
- Other (structural domain of viral envelope glycoprotein), Viral envelope protein subunit
01
Overview
The gp120 C5 region is one of five conserved domains (C1–C5) within the HIV-1 gp120 glycoprotein, a key viral envelope protein involved in host cell entry. While much of gp120 is variable to evade immune detection, C5 is relatively conserved and contributes to stabilizing the envelope structure and facilitating the association between gp120 and gp41, crucial for virus-cell fusion[2][6][7]. C5 participates in antigenic determination, influences envelope processing, and is involved in interactions necessary for functional viral envelope formation. Although this region is not a frequent direct target for clinical drugs, it remains a site of interest for vaccine and antibody development efforts due to its conservation and functional importance[4][5][6].
- Other names
- C5 domain of gp120HIV-1 gp120 C5 regiongp120 C5
02
Mechanism of action
Experimental antibody-based neutralization (targeting structural domains contributing to viral entry) Disruption of gp120-gp41 interaction and envelope processing (hypothetical mechanism based on mutagenesis studies)
03
Biological functions
Facilitates association between gp120 and gp41 during envelope glycoprotein processingContributes to viral envelope stabilizationPlays a role in antigenicity and structure modification, potentially modulating viral adaptationImplicated in the fusion process (via interaction with gp41)Other (structural maintenance of viral glycoprotein complex)
04
Disease associations
Infection (specifically in HIV/AIDS pathogenesis)Other (potential as a target in vaccine and antiviral research)
05
Safety considerations
Therapeutic targeting of conserved envelope regions (like C5) may be limited by antigenic variability, potential for viral escape, and lack of exposed epitopes accessible to neutralizing antibodies[4][5].Structural variability and masking in the viral trimer may reduce therapeutic efficacy[1].
06
Interacting drugs
No specific drugs are documented to target solely the C5 region; most drugs and neutralizing antibodies target larger portions of gp120, such as the CD4 binding site or other conserved/variable regions[4][5]. The C5 region is however part of ongoing vaccine and entry inhibitor design research.
07
Biomarkers
None are routinely used for patient selection or direct efficacy monitoring specific to the C5 region; biomarkers usually relate to HIV viral load or broader gp120 antibody responses.
Beyond the preview
Go deeper on HIV-1 envelope glycoprotein gp120 C5 region (gp120 C5).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HIV-1 envelope glycoprotein gp120 C5 region (gp120 C5).